过继细胞免疫疗法在多发性骨髓瘤中的进展

Progress of adoptive cell therapy in multiple myeloma

多发性骨髓瘤(multiple myeloma,MM)是1种恶性浆细胞肿瘤,目前仍是1种不可治愈的疾病。近几年,过继细胞疗法(adoptive cell therapy,ACT)在血液系统肿瘤中发展迅猛,本文主要综述了从骨髓浸润淋巴细胞到基因改造T细胞,再到NK细胞在MM中的应用进展。总的来说,多发性骨髓瘤的ACT疗法逐渐向高特异性、强杀伤力方向发展,但寻找特异性靶向抗原及预防治疗毒性作用仍是ACT的两大难题。

Multiple myeloma(MM)is a malignant plasma cell tumor.It is still an incurable disease at present.Recently,adoptive cell therapy(ACT)has developed rapidly in hematological malignancies.The application progresses of bone marrow infiltrating lymphocytes to gene modified T cells and NK cells in MM are reviewed in this paper.In general,the MM's ACT is developing toward higher specificity and more powerful,but finding specific targeting antigens and preventing toxic effects remain the two major challenges for ACT.